222 related articles for article (PubMed ID: 20210246)
1. Enhancing apoptosis and overcoming resistance of gemcitabine in pancreatic cancer with bortezomib: a role of death-associated protein kinase-related apoptosis-inducing protein kinase 1.
Guo Q; Chen Y; Wu Y
Tumori; 2009; 95(6):796-803. PubMed ID: 20210246
[TBL] [Abstract][Full Text] [Related]
2. Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.
Tang ZY; Wu YL; Gao SL; Shen HW
J Surg Res; 2008 Mar; 145(1):111-23. PubMed ID: 17714734
[TBL] [Abstract][Full Text] [Related]
3. Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Wissniowski TT; Meister S; Hahn EG; Kalden JR; Voll R; Ocker M
Int J Oncol; 2012 May; 40(5):1581-9. PubMed ID: 22266985
[TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Denlinger CE; Rundall BK; Keller MD; Jones DR
Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y
Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells.
Chien W; Ding LW; Sun QY; Torres-Fernandez LA; Tan SZ; Xiao J; Lim SL; Garg M; Lee KL; Kitajima S; Takao S; Leong WZ; Sun H; Tokatly I; Poellinger L; Gery S; Koeffler PH
Oncotarget; 2014 Jul; 5(13):4881-94. PubMed ID: 24952679
[TBL] [Abstract][Full Text] [Related]
7. Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine.
Chandler NM; Canete JJ; Callery MP
J Gastrointest Surg; 2004 Dec; 8(8):1072-8. PubMed ID: 15585396
[TBL] [Abstract][Full Text] [Related]
8. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.
Kamat AM; Karashima T; Davis DW; Lashinger L; Bar-Eli M; Millikan R; Shen Y; Dinney CP; McConkey DJ
Mol Cancer Ther; 2004 Mar; 3(3):279-90. PubMed ID: 15026548
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.
Ng SSW ; Tsao MS; Chow S; Hedley DW
Cancer Res; 2000 Oct; 60(19):5451-5. PubMed ID: 11034087
[TBL] [Abstract][Full Text] [Related]
10. hTERT-siRNA could potentiate the cytotoxic effect of gemcitabine to pancreatic cancer cells Bxpc-3.
Tan J; Zhou X; Zhu H
Exp Clin Transplant; 2012 Aug; 10(4):386-93. PubMed ID: 22757972
[TBL] [Abstract][Full Text] [Related]
11. Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.
Gao CC; Xu XL; Li F; Gong BG; Liu S; Cui YQ; Sun HC; Xu PY; Zheng YM; Jiang H
Tumour Biol; 2016 Jun; 37(6):7555-64. PubMed ID: 26684804
[TBL] [Abstract][Full Text] [Related]
12. Chemosensitivity induced by down-regulation of microRNA-21 in gemcitabine-resistant pancreatic cancer cells by indole-3-carbinol.
Paik WH; Kim HR; Park JK; Song BJ; Lee SH; Hwang JH
Anticancer Res; 2013 Apr; 33(4):1473-81. PubMed ID: 23564788
[TBL] [Abstract][Full Text] [Related]
13. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome.
Bold RJ; Virudachalam S; McConkey DJ
J Surg Res; 2001 Sep; 100(1):11-7. PubMed ID: 11516199
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma.
Märten A; Zeiss N; Serba S; Mehrle S; von Lilienfeld-Toal M; Schmidt J
Mol Cancer Ther; 2008 Nov; 7(11):3624-31. PubMed ID: 19001444
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
[TBL] [Abstract][Full Text] [Related]
16. Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells.
Kim DJ; Park YS; Kang MG; You YM; Jung Y; Koo H; Kim JA; Kim MJ; Hong SM; Lee KB; Jang JJ; Park KC; Yeom YI
Exp Cell Res; 2015 Aug; 336(1):119-29. PubMed ID: 26112218
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide.
Fryer RA; Barlett B; Galustian C; Dalgleish AG
Anticancer Res; 2011 Nov; 31(11):3747-56. PubMed ID: 22110196
[TBL] [Abstract][Full Text] [Related]
18. Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine.
Shimasaki T; Ishigaki Y; Nakamura Y; Takata T; Nakaya N; Nakajima H; Sato I; Zhao X; Kitano A; Kawakami K; Tanaka T; Takegami T; Tomosugi N; Minamoto T; Motoo Y
J Gastroenterol; 2012 Mar; 47(3):321-33. PubMed ID: 22041920
[TBL] [Abstract][Full Text] [Related]
19. Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer.
Fahy BN; Schlieman MG; Virudachalam S; Bold RJ
J Surg Res; 2003 Jul; 113(1):88-95. PubMed ID: 12943815
[TBL] [Abstract][Full Text] [Related]
20. Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.
Lee JK; Ryu JK; Yang KY; Woo SM; Park JK; Yoon WJ; Lee SH; Jeong KS; Kim YT; Yoon YB
Pancreas; 2011 Aug; 40(6):966-73. PubMed ID: 21487323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
